Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
7 October 2014 |
Main ID: |
EUCTR2005-005326-30-BE |
Date of registration:
|
01/03/2006 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOX
|
Scientific title:
|
International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0 mg) once a week and SR34006 (2.5 mg) once a week, documenting the safety and efficacy of both compounds during a 6-month treatment, and demonstrating the neutralizing effect of SSR29261 on the SSR126517E-induced anti-Xa activity. - EQUINOX |
Date of first enrolment:
|
24/04/2006 |
Target sample size:
|
700 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005326-30 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: yes
Other specify the comparator: Idraparinux sodium
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Belgium
|
Czech Republic
|
Denmark
|
Italy
|
Spain
| | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Confirmed acute symptomatic DVT of the lower limbs. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1-Exclusion criteria before initial randomization: Legal lower age limitations (country specific). Creatinine clearance < 30 mL/min. Severe hepatic disease. Bacterial endocarditis. Active bleeding or high risk for bleeding. Uncontrolled hypertension: systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg. Pregnancy or childbearing potential without proper contraceptive measures. Breastfeeding. Known allergy to idraparinux, SSR126517E, or egg proteins. -Criteria related to study methodology Written informed consent not signed. Indication of prolonged anticoagulation for other reason than DVT of the lower limbs. Symtomatic pulmonary embolism (PE). Any administration or intended use of a fibrinolytic agent, thrombectomy, insertion of a caval filter, to treat the current episode of DVT. More than 36 hours pre-randomization treatment with therapeutic dosages of (LMW) Heparin, fondaparinux or initiation of VKA treatment prior to randomization Life expectancy < 6 months. Participation in another pharmacotherapeutic study within the prior 30 days. Impossibility to meet protocol requirements.
2-Exclusion criteria at the end of the 6-month treatment period for participation in the avidin neutralizing effect assessment Patient receiving open-label avidin during the study. Patient requiring more than 6-month anticoagulant treatment.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Patients with confirmed acute symptomatic DVT of the lower limbs MedDRA version: 8.1
Level: PT
Classification code 10051055
|
Intervention(s)
|
Product Name: Idraparinux Product Code: SR34006 Pharmaceutical Form: Solution for injection INN or Proposed INN: Idraparinux sodium CAS Number: 149920-56-9 Current Sponsor code: SR34006 Other descriptive name: SR34006A Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5-
Product Name: Biotinylated Idraparinux Product Code: SSR126517 Pharmaceutical Form: Solution for injection CAS Number: 405159-59-3 Current Sponsor code: SSR126517 Other descriptive name: SSR126517E Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6-
Product Name: Avidin Product Code: SSR29261 Pharmaceutical Form: Powder for injection* CAS Number: 1405-69-2 Current Sponsor code: SSR29261 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Powder for injection* Route of administration of the placebo: Intravenous drip use (Noncurrent)
|
Primary Outcome(s)
|
Secondary Objective: To assess the time course to steady state achievement of SSR126517E/SR34006. To provide safety and efficacy data on biotinylated idraparinux (SSR126517E) compared to idraparinux (SR34006).
|
Main Objective: -Primary objective of the bioequipotency assessment: To demonstrate the bioequipotency of biotinylated idraparinux (SSR126517E) and idraparinux (SR34006) at steady state, in patients, with acute symptomatic DVT, as assessed by anti-Xa activity. -Primary objective of the avidin neutralizing effect assessment: To demonstrate the neutralizing effect of avidin (SSR29261) on anti-Xa activity induced by biotinylated idraparinux (SSR126517E).
|
Primary end point(s): PRIMARY ENDPOINTS AND MAIN SECONDARY ENDPOINTS: 1-Bioequipotency assessment, avidin neutralizing effect assessment and time course to steady state achievement The PD variable is the anti-Xa activity, measured without excess of antithrombin (AT), relative to the maximal effect in a pool of plasma from healthy volunteers. The PK variable is the anti-Xa activity, measured with excess of AT. 2-Safety assessment The main two-safety outcome events are bleeding, reported as either AE or SAE, and validated by the CIAC, and death (cause of death validated by the CIAC). 3-Efficacy assessment The main efficacy outcome is symptomatic recurrent DVT/PE (fatal or not), as validated by the CIAC.
|
Secondary ID(s)
|
2005-005326-30-AT
|
EFC5945
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|